AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28732512 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged admission in an acute or post-acute care facility
Number of subjects: 89
Study 28732512 — intervention group
Group type: COMPARATOR
Intervention: Discharged to home
Number of subjects: 89
Study 28732512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (prolonged admission and discharged to home)
Number of subjects: 89
Study 28732512 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 89
Study 25828994 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent anemia and inflammation (CRP ≥ 10 mg/L)
Number of subjects: 470
Study 25828994 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia without inflammation
Number of subjects: 470
Study 25828994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation without anemia
Number of subjects: 470
Study 25828994 — intervention group
Group type: COMPARATOR
Intervention: No anemia and no inflammation
Number of subjects: 470
Study 23713032 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 8
Study 23713032 — intervention group
Group type: COMPARATOR
Intervention: Parasympathetic blockade (glycopyrrolate)
Number of subjects: 8
Study 23713032 — intervention group
Group type: COMPARATOR
Intervention: β‐adrenergic blockade (metoprolol)
Number of subjects: 8
Study 23713032 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug) during PEI after leg cycling
Number of subjects: 8
Study 23713032 — intervention group
Group type: COMPARATOR
Intervention: β‐adrenergic blockade (metoprolol) during PEI after leg cycling
Number of subjects: 8
Study 23713032 — intervention group
Group type: COMPARATOR
Intervention: Parasympathetic blockade (glycopyrrolate) during PEI after leg cycling
Number of subjects: 8
Study 23713032 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug) during PEI after handgrip
Number of subjects: 8
Study 23713032 — intervention group
Group type: COMPARATOR
Intervention: Parasympathetic blockade (glycopyrrolate) during PEI after handgrip
Number of subjects: 8
Study 23713032 — intervention group
Group type: COMPARATOR
Intervention: β‐adrenergic blockade (metoprolol) during PEI after handgrip
Number of subjects: 8
Study 21787392 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilisation intervention with women's groups facilitated by ASHAs
Number of subjects: 150000
Study 21787392 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150000
Study 19351238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide therapy
Number of subjects: 0
Study 16733237 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in walnuts (20% energy) for 8 weeks
Number of subjects: 62
Study 16733237 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in unsalted cashew nuts (20% energy) for 8 weeks
Number of subjects: 62
Study 16733237 — intervention group
Group type: COMPARATOR
Intervention: Control diet for 8 weeks
Number of subjects: 62
Study 16733237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cashew group
Number of subjects: 62
Study 15345099 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain GG (LGG) milk formula
Number of subjects: 179
Study 15345099 — intervention group
Group type: COMPARATOR
Intervention: Placebo milk formula
Number of subjects: 179
Study 11753767 — intervention group
Group type: EXPERIMENTAL
Intervention: Single event multilevel surgery for gait improvement
Number of subjects: 20
Study 11753767 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy programme (Control)
Number of subjects: 20
Study 11753767 — intervention group
Group type: EXPERIMENTAL
Intervention: Single event multilevel surgery
Number of subjects: 20
Study 9405913 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 19
Study 9405913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8098276 — intervention group
Group type: EXPERIMENTAL
Intervention: Denopamine (20 mg)
Number of subjects: 19
Study 8098276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2957943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrahepatic therapy (14-day continuous infusion of fluorodeoxyuridine at 0.3 mg/kg body weight per day)
Number of subjects: 162
Study 2957943 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy (14-day continuous infusion of fluorodeoxyuridine at 0.15 mg/kg body weight per day)
Number of subjects: 162
Study 2957943 — intervention group
Group type: COMPARATOR
Intervention: Crossover from systemic to intrahepatic therapy after tumor progression
Number of subjects: 162
Study 2957943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrahepatic therapy
Number of subjects: 162
Study 2957943 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy
Number of subjects: 162
Study 2957943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrahepatic group
Number of subjects: 162
Study 2957943 — intervention group
Group type: COMPARATOR
Intervention: Systemic group
Number of subjects: 162
Study 31941381 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3044
Study 31941381 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 3044
Study 28753030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and Bee Venom Acupuncture (BVA)
Number of subjects: 73
Study 28753030 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture and normal saline injections
Number of subjects: 73
Study 28753030 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with anti-parkinsonian drugs
Number of subjects: 73
Study 26847230 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfers (US$5, plus US$1 increment at every subsequent visit)
Number of subjects: 433
Study 26847230 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 433
Study 26847230 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfers
Number of subjects: 433
Study 25678098 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (doses ranging from 2.5 to 20.0 mg once daily)
Number of subjects: 1060
Study 25678098 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone (25 mg every second day to 50 mg once daily for 90 days)
Number of subjects: 1060
Study 25678098 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 1060
Study 24028234 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based tobacco control intervention
Number of subjects: 72
Study 24028234 — intervention group
Group type: COMPARATOR
Intervention: Delayed-intervention control
Number of subjects: 72
Study 21921249 — intervention group
Group type: EXPERIMENTAL
Intervention: Hall Technique (HT)
Number of subjects: 132
Study 21921249 — intervention group
Group type: COMPARATOR
Intervention: General Dental Practitioners' (GDPs) standard restorations (control)
Number of subjects: 132
Study 19006209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition assessed by Wechsler scale subtests
Number of subjects: 31
Study 19006209 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior assessed by parent-questionnaires
Number of subjects: 31
Study 19006209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-related breathing disorders (SRBD) assessed by polysomnography
Number of subjects: 31
Study 19006209 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance subtest scores
Number of subjects: 31
Study 19006209 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 31
Study 19006209 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobehavioral abnormalities
Number of subjects: 31
Study 19006209 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of neurobehavioral abnormalities with SRBD
Number of subjects: 31
Study 16978997 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 2340
Study 16978997 — intervention group
Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 2340
Study 12767565 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg of intravaginal misoprostol
Number of subjects: 120
Study 12767565 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg of intravaginal misoprostol
Number of subjects: 120
Study 10562113 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced nurse practitioner intervention in cardiovascular medicine
Number of subjects: 0
Study 10562113 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8804228 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 0
Study 8804228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive agents (dopamine)
Number of subjects: 0
Study 8804228 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factors and atrial natriuretic peptide
Number of subjects: 0
Study 8804228 — intervention group
Group type: COMPARATOR
Intervention: Continuous renal replacement therapy
Number of subjects: 0
Study 8804228 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible membranes
Number of subjects: 0
Study 1832181 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids and H2-antagonists
Number of subjects: 0
Study 1832181 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 0
Study 1832181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 0
Study 1832181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0
Study 6859790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 18
Study 6859790 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 18
Study 6859790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and metoprolol
Number of subjects: 18
Study 6859790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30959242 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste
Number of subjects: 35
Study 30959242 — intervention group
Group type: COMPARATOR
Intervention: No Taste
Number of subjects: 35
Study 30959242 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie real food cues
Number of subjects: 35
Study 29405785 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HRT)
Number of subjects: 6993
Study 29405785 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 6993
Study 26550687 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol 100/25 μg
Number of subjects: 45
Study 26550687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25155600 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (200 mg single dose)
Number of subjects: 56
Study 25155600 — intervention group
Group type: COMPARATOR
Intervention: Boceprevir (800 mg every 8 hours for 10 days)
Number of subjects: 56
Study 25155600 — intervention group
Group type: COMPARATOR
Intervention: Telaprevir (750 mg every 8 hours for 10 days)
Number of subjects: 56
Study 25155600 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (200 mg single dose with boceprevir or telaprevir)
Number of subjects: 56
Study 22549173 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 90
Study 22549173 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo massage
Number of subjects: 90
Study 22549173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 20511481 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil, 1200 mg
Number of subjects: 327
Study 20511481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 18794746 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized physical therapy and exercise, standardized self-training program, and back education
Number of subjects: 45
Study 18794746 — intervention group
Group type: COMPARATOR
Intervention: Self-training program and back education (no individualized therapy)
Number of subjects: 45
Study 16083789 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with genetically modified Bet v 1 derivatives (trimer and fragments)
Number of subjects: 23
Study 16083789 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with genetically modified Bet v 1 derivatives
Number of subjects: 23
Study 16083789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12271286 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5% cream, applied 3 times a week for up to 16 weeks
Number of subjects: 5
Study 9672959 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom program
Number of subjects: 1074
Study 9672959 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom program plus a semester-long school-as-community component
Number of subjects: 1074
Study 9672959 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 1074
Study 7852871 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified fibrinogen from insulin-dependent diabetics
Number of subjects: 22
Study 7852871 — intervention group
Group type: COMPARATOR
Intervention: Purified fibrinogen from healthy subjects
Number of subjects: 22
Study 2810139 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback training only
Number of subjects: 24
Study 2810139 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback training + instructions and modeling for rest position
Number of subjects: 24
Study 2810139 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback training + prosthetic guide (6.8 mm spacing)
Number of subjects: 24
Study 2810139 — intervention group
Group type: COMPARATOR
Intervention: Control group (biofeedback only)
Number of subjects: 24
Study 2810139 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study 31965526 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person lifestyle intervention (LI)
Number of subjects: 208
Study 31965526 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone lifestyle intervention (LI)
Number of subjects: 208
Study 31965526 — intervention group
Group type: COMPARATOR
Intervention: Medical nutrition therapy (MNT)
Number of subjects: 208
Study 31965526 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 208
Study 29217129 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified BPD‐DS with a long alimentary limb (1 m from Treitz ligament)
Number of subjects: 20
Study 29217129 — intervention group
Group type: COMPARATOR
Intervention: Standard BPD‐DS (strict alimentary limb of 1.5 m)
Number of subjects: 20
Study 26720599 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning program (training group, n=57)
Number of subjects: 113
Study 26720599 — intervention group
Group type: COMPARATOR
Intervention: no-training group (control group, n=56)
Number of subjects: 113
Study 26720599 — intervention group
Group type: COMPARATOR
Intervention: no-training group (control group)
Number of subjects: 113
Study 26720599 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning program (training group)
Number of subjects: 113
Study 26720599 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors (first test)
Number of subjects: 113
Study 26720599 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives (first test)
Number of subjects: 113
Study 26720599 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors (second test, training group)
Number of subjects: 113
Study 26720599 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives (second test, training group)
Number of subjects: 113
Study 24947106 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive stimulation
Number of subjects: 1489
Study 24947106 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrition
Number of subjects: 1489
Study 24947106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of responsive stimulation and enhanced nutrition
Number of subjects: 1489
Study 24947106 — intervention group
Group type: COMPARATOR
Intervention: Routine health and nutrition services (Control)
Number of subjects: 1489
Study 23673269 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) infusion
Number of subjects: 2
Study 23673269 — intervention group
Group type: COMPARATOR
Intervention: EP4 receptor antagonist BGC20‐1531
Number of subjects: 2
Study 23673269 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin F2α (PGF2α) infusion
Number of subjects: 2
Study 20827017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone aceponate (0.127%) lipophilic cream applied twice daily
Number of subjects: 415
Study 18221398 — intervention group
Group type: COMPARATOR
Intervention: GHRH + ARG (1 microg/kg body weight i.v. GHRH followed by 0.5 g/kg body weight i.v. arginine hydrochloride)
Number of subjects: 15
Study 18221398 — intervention group
Group type: COMPARATOR
Intervention: Ghrelin (1 microg/kg body weight i.v. acylated ghrelin)
Number of subjects: 15
Study 15893293 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0
Study 15893293 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 0
Study 12513038 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate daily
Number of subjects: 2763
Study 12513038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study 11377905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroview IOL (Bausch & Lomb)
Number of subjects: 100
Study 11377905 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IOL (Alcon)
Number of subjects: 100
Study 11377905 — intervention group
Group type: EXPERIMENTAL
Intervention: MemoryLens IOL (ORC)
Number of subjects: 100
Study 11377905 — intervention group
Group type: EXPERIMENTAL
Intervention: CeeOn 920 IOL (Pharmacia)
Number of subjects: 100
Study 9204355 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopentol (Imagopaque 250 mg I/ml)
Number of subjects: 116
Study 9204355 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate (Urografin 219 mg I/ml)
Number of subjects: 116
Study 8201703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial thrombolytic therapy (urokinase)
Number of subjects: 114
Study 8201703 — intervention group
Group type: COMPARATOR
Intervention: Operative intervention
Number of subjects: 114
Study 2444000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (CFZ) 4 days (16 X 0.5 g)
Number of subjects: 1384
Study 2444000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 2 days (4 X 1.5 g)
Number of subjects: 1384
Study 2444000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (CFZ) 1 day (4 X 0.5 g)
Number of subjects: 1384
Study 2087142 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotropin
Number of subjects: 12
Study 2087142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1146747 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives with vitamin B6 deficiency
Number of subjects: 13
Study 1146747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation
Number of subjects: 13
Study 1146747 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 deficiency (Control)
Number of subjects: 13
Study 30396006 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley beta glucans (6 g in experimental bread)
Number of subjects: 43
Study 30396006 — intervention group
Group type: COMPARATOR
Intervention: Control group (equal bread without beta glucans)
Number of subjects: 43
Study 28915981 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS-2/100Hz
Number of subjects: 481
Study 28915981 — intervention group
Group type: COMPARATOR
Intervention: TEAS-2Hz
Number of subjects: 481
Study 28915981 — intervention group
Group type: COMPARATOR
Intervention: TEAS-100Hz
Number of subjects: 481
Study 28915981 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 481
Study 25873144 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 316
Study 25873144 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 316
Study 25873144 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII and MDI
Number of subjects: 316
Study 22836615 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 34
Study 22836615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 21177770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Switch-2-Activity programme)
Number of subjects: 1048
Study 20040086 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-2 h (20,000 U/kg for 2 hours)
Number of subjects: 129
Study 20040086 — intervention group
Group type: COMPARATOR
Intervention: UK-12 h (2,200 U/kg.h for 12 hours)
Number of subjects: 129
Study 20040086 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-2 h
Number of subjects: 129
Study 20040086 — intervention group
Group type: COMPARATOR
Intervention: UK-12 h
Number of subjects: 129
Study 17597141 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-event children
Number of subjects: 0
Study 17597141 — intervention group
Group type: COMPARATOR
Intervention: Repeat-event children
Number of subjects: 0
Study 17597141 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress influence
Number of subjects: 0
Study 17597141 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress effects
Number of subjects: 0
Study 14648009 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 1172
Study 14648009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1172
Study 11495617 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance (n = 293)
Number of subjects: 874
Study 11495617 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (n = 289)
Number of subjects: 874
Study 11495617 — intervention group
Group type: COMPARATOR
Intervention: Advice (n = 292)
Number of subjects: 874
Study 9609375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable barrier membrane
Number of subjects: 10